RecruitingNCT07493317
Tocilizumab for depression with signs of immune activation
About this title
Read the official source — NCT07493317Medication studyAges 18–70United States
Understand this study
Who could participate?
Listed age limits: 18 years to 70 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 26, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 60
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT07493317
- Official title
Show the full official title
Neutralizing Interleukin (IL)-6 Signaling to Reverse Immune Related Anhedonia in Patients With Major Depressive Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Icahn School of Medicine at Mount Sinai, a university.
Does this study involve medication?
Yes. The study involves medication, including Tocilizumab.
Who can participate?
Listed age limits: 18 years to 70 years.
Is this study still recruiting?
The registry lists this study as recruiting.
